

IM

Docket No. DRF 3.3-087

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

CERTIFICATION UNDER 37 CFR 1.10

The undersigned hereby certifies that this correspondence, and all documents referred to as being enclosed herewith, is being deposited with the United States Postal Service on this date <u>December 6, 2006</u> in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EV 504212959 US</u>, addressed to: Commissioner For Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Joan Aftisiewsk

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jagattaran DAS, et al.

Application No.: 10/589,771

Filed: August 17, 2006

For: NOVEL TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS

AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Form PTO/SB/08a be considered and made of record in the above-identified patent application. Required copies of these documents are enclosed.

No fee is believed to be due because this Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits. However, the Commissioner is authorized to charge our **Deposit Account No.** <u>50-3221</u> for the required amount in the event that a fee is now due.

Respectfully submitted,

Dated: December 17, 2006

By:

Milagros A. Cepeda Reg. No.: 33,365 Attorney for Applicant

Telephone No.: (908) 203-6505

Dr. Reddy's Laboratories, Inc. 200 Somerset Corporate Blvd., 7th Fl. Bridgewater, NJ 08807

FAX: (908) 203-6515

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
OF Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589771	
Filing Date		2006-08-17	
First Named Inventor	Jagat	taran DAS	
Art Unit			-
Examiner Name	To be assigned		
Attorney Docket Number		DRF 3.3-087	

				U	.S.PATENTS					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6054471		2000-04-25	Markus Schm	Markus Schmutz				
If you wish	h to ac	⊔ dd additional U.S. Pate	nt citatio	n informatior	n please click the	e Add button.				
			U.S.P.	ATENT APP	LICATION PUE	BLICATIONS				
Examiner Initial*	Cite No	Publication Number	Kind Code ¹			of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wish	to ac	dd additional U.S. Publi					button			
				FOREIGN P	ATENT DOCUM	MENTS	_			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Name of Patentee Applicant of cited Document	101 N	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5	
	1	0304221	EP	A2	1989-02-22	Merck & Co., Inc.			Ģ	
	2	03/059894	wo	A1	2003-07-24	Dr. Reddy's Labora	tories			
lf you wish	to ad	d additional Foreign Pa	atent Do	cument citati	on information p	lease click the Add	button			
					TERATURE DO					

			Application Number		10589771			
			Filing Date		2006-08-17			
1		TION DISCLOSUR	- 1	First Named Inventor	Jagatt	taran DAS		tivity of N-I4-(Azolyl)
		NT BY APPLICAN		Art Unit		-		
O'ST TOT	See Sin	ssion under 37 CFR 1.9	9)	Examiner Name	To be	assigned		
DECUR	5008	ਲ)	,	Attorney Docket Number	e,r	DRF 3.3-087		
STATE THAT	,							
Examiner Initials*	Cite No	Include name of the auth (book, magazine, journal publisher, city and/or cou	l, serial,	symposium, catalog, etc	of the c), dat	e article (when approp e, pages(s), volume-is	riate), title of the item ssue number(s),	T 5
	1	Tommoyuki KITAZAKI, et al phenyl]-and N-[4-(Azolylme propyl]-azolones, Chem. Ph	tyl)pheny	/I]-N'-[(1R,2R)-2-(2,4-difluo	rophen	Synthesis and Antifunganyl)-2-hydroxy-1-methyl-	al Activity of N-[4-(Azolyl) 3-(1H-1,2,4-triazol-1-yl)	
	2	Richard J. BOCHIS, et al., E	Benzylate	ed 1,2,3-Triazoles as Antico	occidio	stats, J. Med Chem., 34	, pp. 2843-2852 (1991).	
	3	Laszlo HAZAI and Gyula DE 1,4-Dihydroisoquinolin-3(2H	EAK, Hyd I)-ones, J	drogenation of Substituted J. Heterocyclic Chem., 26,	1-Arylis pp. 609	soquinolin-3(2H)-ones to 9-612 (1989).	5,6,7,8-Tetrahydro- and	
If you wish	n to ad	d additional non-patent lit	erature	document citation inform	nation	please click the Add t	l outton	
				EXAMINER SIGNATION	-	•		
Examiner	Signat	ure			···	Date Considered		
*EXAMINE	ER: Ini	tial if reference considered	d, wheth	ner or not citation is in co	onform	nance with MPEP 609	. Draw line through a	

¹ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE		10589771	10589771		
		2006-08-17	2006-08-17		
		Jagattaran DAS	taran DAS		
	Art Unit				
(Not for submission under 37 CFR 1.99)		To be assigned			
	Attorney Docket Numb	per DRF 3.3-087	DRF 3.3-087		
97 and 1.98 to make the	CERTIFICATION STA appropriate selection(s):	FEMENT			
of information contained in a counterpart.	in the information disclopart foreign application r	sure statement wa	s first cited in any communication e months prior to the filing of the		
fice in a counterpart fore sonable inquiry, no item c esignated in 37 CFR 1.56	ign application, and, to to find information contained it	he knowledge of t n the information o	he person signing the certification lisclosure statement was known to		
tification statement.					
7 CFR 1.17 (p) has been	submitted herewith.				
u ,					
olicant or representative is	SIGNATURE s required in accordance	with CFR 1.33, 10.	18. Please see CFR 1.4(d) for the		
Julyn & C	e e de Date	(YYYY-MM-DD)	2006-12-06		
1	and 1.98 to make the of information contained atent office in a counterposure statement. See 37 (and information contained in fice in a counterpart fore sonable inquiry, no item of the seignated in 37 CFR 1.56 (and information contained in the seignated in 37 CFR 1.56 (b) (c) (c) (c) (c) (c) (d) (d) (d) (d) (d) (e) (e) (e) (e) (finite or in the seignated in the	Art Unit Examiner Name Attorney Docket Numb CERTIFICATION STATE 97 and 1.98 to make the appropriate selection(s): of information contained in the information disclosuratent office in a counterpart foreign application resure statement. See 37 CFR 1.97(e)(1). information contained in the information disclosure in a counterpart foreign application, and, to the sonable inquiry, no item of information contained in the esignated in 37 CFR 1.56(c) more than three more 7 CFR 1.97(e)(2). tification statement. 7 CFR 1.17 (p) has been submitted herewith.	First Named Inventor Art Unit Examiner Name Attorney Docket Number DRF 3.3-087 CERTIFICATION STATEMENT 1.97 and 1.98 to make the appropriate selection(s): Of information contained in the information disclosure statement was attent office in a counterpart foreign application not more than three boure statement. See 37 CFR 1.97(e)(1). Information contained in the information disclosure statement was fice in a counterpart foreign application, and, to the knowledge of the sonable inquiry, no item of information contained in the information contained in 37 CFR 1.56(c) more than three months prior to the first CFR 1.97(e)(2). Itification statement. 7 CFR 1.17 (p) has been submitted herewith.		

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**